These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1060 related articles for article (PubMed ID: 27220757)

  • 81. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
    Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
    [TBL] [Abstract][Full Text] [Related]  

  • 82. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
    Ziemann M; Altermann W; Angert K; Arns W; Bachmann A; Bakchoul T; Banas B; von Borstel A; Budde K; Ditt V; Einecke G; Eisenberger U; Feldkamp T; Görg S; Guthoff M; Habicht A; Hallensleben M; Heinemann FM; Hessler N; Hugo C; Kaufmann M; Kauke T; Koch M; König IR; Kurschat C; Lehmann C; Marget M; Mühlfeld A; Nitschke M; Pego da Silva L; Quick C; Rahmel A; Rath T; Reinke P; Renders L; Sommer F; Spriewald B; Staeck O; Stippel D; Süsal C; Thiele B; Zecher D; Lachmann N
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1056-1066. PubMed ID: 31213508
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation.
    Rao S; Ghanta M; Lee IJ; Gillespie A; Parekh HK; Geier SS; Zeng X; Karachristos A; Lau KN; Karhadkar S; Di Carlo A; Sifontis NM; Constantinescu S
    Clin Transpl; 2014; ():143-51. PubMed ID: 26281139
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Differential Impact of Delayed Graft Function in Deceased Donor Renal Transplant Recipients With and Without Donor-specific HLA-antibodies.
    Haller J; Wehmeier C; Hönger G; Hirt-Minkowski P; Gürke L; Wolff T; Steiger J; Amico P; Dickenmann M; Schaub S
    Transplantation; 2019 Sep; 103(9):e273-e280. PubMed ID: 31205266
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
    Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
    Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation.
    Musat AI; Pigott CM; Ellis TM; Agni RM; Leverson GE; Powell AJ; Richards KR; D'Alessandro AM; Lucey MR
    Liver Transpl; 2013 Oct; 19(10):1132-41. PubMed ID: 23873778
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
    Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
    Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.
    Babu A; Andreou A; Briggs D; Krishnan N; Higgins R; Mitchell D; Barber T; Daga S
    Clin Transpl; 2016; 32():173-179. PubMed ID: 28564535
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical relevance of pre- and post-transplant HLA antibodies, donor-specific, and nondonor-specific HLA antibodies detected by ELISA in renal transplantation.
    Lee PC; Chen YL; Wang WM; Tu WC; Chen HY
    Clin Transpl; 2013; ():385-91. PubMed ID: 25095533
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
    Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
    Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations.
    Dieplinger G; Ditt V; Arns W; Huppertz A; Kisner T; Hellmich M; Bauerfeind U; Stippel DL
    Transpl Int; 2014 Jan; 27(1):60-8. PubMed ID: 24131087
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Association of positive pre-transplant angiotensin II type 1 receptor antibodies with clinical outcomes in lung transplant recipients.
    Son BS; Lee HJ; Cho WH; So MW; Park JM; Yeo HJ
    Transpl Immunol; 2023 Oct; 80():101901. PubMed ID: 37442212
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
    Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
    Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
    [TBL] [Abstract][Full Text] [Related]  

  • 97. HLA Class II Antibodies at the Time of Kidney Transplantation and Cardiovascular Outcome: A Retrospective Cohort Study.
    Malfait T; Emonds MP; Daniëls L; Nagler EV; Van Biesen W; Van Laecke S
    Transplantation; 2020 Apr; 104(4):823-834. PubMed ID: 31369517
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes.
    Redondo-Pachón D; Pérez-Sáez MJ; Mir M; Gimeno J; Llinás L; García C; Hernández JJ; Yélamos J; Pascual J; Crespo M
    Hum Immunol; 2018 Jun; 79(6):424-431. PubMed ID: 29524568
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
    Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
    Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prevalence of AT1R antibody (AT1R-Ab) among Malaysian multi-ethnic population.
    Jalalonmuhali M; Caroll R; Deayton S; Emery T; Humphreys I; Lim SJ; Lim SK; Coates T
    Hum Immunol; 2020 Dec; 81(12):679-684. PubMed ID: 32736900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.